Analyst Price Targets — CHRS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 24, 2025 1:04 pm | Ashwani Verma | UBS | $1.05 | $1.05 | TheFly | Coherus Biosciences price target lowered to $1.05 from $1.50 at UBS |
| December 5, 2024 11:50 am | Colleen Kusy | Robert W. Baird | $6.00 | $1.74 | StreetInsider | Coherus Biosciences (CHRS) PT Raised to $6 at Baird |
| November 14, 2022 7:56 am | — | J.P. Morgan | $11.00 | $7.79 | Benzinga | JP Morgan Maintains Neutral on Coherus BioSciences, Lowers Price Target to $11 |
| June 13, 2022 9:01 pm | Ashwani Verma | UBS | $7.00 | $6.19 | TheFly | Coherus Biosciences initiated with a Neutral at UBS |
Latest News for CHRS
Coherus Oncology (CHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Shares of Coherus Oncology, Inc. (NASDAQ: CHRS - Get Free Report) have received an average rating of "Hold" from the five ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating
Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript
Coherus Oncology (CHRS) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.28 per share a year ago.
– LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 million in year ending cash, cash equivalents and marketable securities – – Conference call today at 4:30 p.m. Eastern Standard Time – REDWOOD CITY, Calif.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CHRS.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.